Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 535
- Registration Number
- NCT01677182
Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 393
- Registration Number
- NCT01647542
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 104
- Registration Number
- NCT01642602
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
Phase 2
Completed
- Conditions
- Gastroesophageal Reflux DiseaseErosive Esophagitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 63
- Registration Number
- NCT01642615
Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants
Phase 1
Completed
- Conditions
- Calcium DeficiencyVitamin D Deficiency
- Interventions
- Other: Low calcium meals
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2013-10-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 55
- Registration Number
- NCT01639222
Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 193099
- Registration Number
- NCT01637935
Double-blind Comparative Study of SYR-472
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 245
- Registration Number
- NCT01632007
A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 19
- Registration Number
- NCT01630746
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
Phase 3
Terminated
- Conditions
- Type 2 DiabetesCardiovascular Disease
- Interventions
- Drug: TAK-875 Placebo
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3207
- Registration Number
- NCT01609582
Norovirus Bivalent-Vaccine Efficacy Study
Phase 1
Completed
- Conditions
- Prevention From Norovirus Infection
- Interventions
- Biological: Norovirus Bivalent VaccineBiological: Saline Comparator
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 132
- Registration Number
- NCT01609257
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Emory University, Atlanta, Georgia, United States
© Copyright 2025. All Rights Reserved by MedPath